|Impact of FDG-PET on radiation therapy volume delineation in non–small-cell lung cancer|
J Bradley, WL Thorstad, S Mutic, TR Miller, F Dehdashti, BA Siegel, ...
International Journal of Radiation Oncology* Biology* Physics 59 (1), 78-86, 2004
|Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)|
FG Fernandez, JA Drebin, DC Linehan, F Dehdashti, BA Siegel, ...
Annals of surgery 240 (3), 438, 2004
|A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy|
KSC Chao, WR Bosch, S Mutic, JS Lewis, F Dehdashti, MA Mintun, ...
International Journal of Radiation Oncology* Biology* Physics 49 (4), 1171-1182, 2001
|Lymph node staging by positron emission tomography in patients with carcinoma of the cervix|
PW Grigsby, BA Siegel, F Dehdashti
Journal of Clinical Oncology 19 (17), 3745-3749, 2001
|Metabolic flare: indicator of hormone responsiveness in advanced breast cancer|
JE Mortimer, F Dehdashti, BA Siegel, K Trinkaus, JA Katzenellenbogen, ...
Journal of Clinical Oncology 19 (11), 2797-2803, 2001
|In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM|
F Dehdashti, MA Mintun, JS Lewis, J Bradley, R Govindan, R Laforest, ...
European journal of nuclear medicine and molecular imaging 30 (6), 844-850, 2003
|Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response—a preliminary report|
F Dehdashti, PW Grigsby, MA Mintun, JS Lewis, BA Siegel, MJ Welch
International Journal of Radiation Oncology* Biology* Physics 55 (5), 1233-1238, 2003
|FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features|
KL Berger, SA Nicholson, F Dehdashti, BA Siegel
American Journal of Roentgenology 174 (4), 1005-1008, 2000
|Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum|
MH Whiteford, HM Whiteford, LF Yee, OA Ogunbiyi, F Dehdashti, ...
Diseases of the colon & rectum 43 (6), 759-767, 2000
|Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays|
F Dehdashti, JE Mortimer, BA Siegel, LK Griffeth, TJ Bonasera, ...
Journal of Nuclear Medicine 36 (10), 1766-1774, 1995
|Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.|
FL Flanagan, F Dehdashti, BA Siegel, DD Trask, SR Sundaresan, ...
AJR. American journal of roentgenology 168 (2), 417-424, 1997
|Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography|
MS Cohen, N Arslan, F Dehdashti, GM Doherty, TC Lairmore, LM Brunt, ...
Surgery 130 (6), 941-946, 2001
|11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse|
N Oyama, TR Miller, F Dehdashti, BA Siegel, KC Fischer, JM Michalski, ...
Journal of Nuclear Medicine 44 (4), 549-555, 2003
|64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors|
CJ Anderson, F Dehdashti, PD Cutler, SW Schwarz, R Laforest, LA Bass, ...
Journal of Nuclear Medicine 42 (2), 213-221, 2001
|18F-FDG PET definition of gross tumor volume for radiotherapy of non–small cell lung cancer: is a single standardized uptake value threshold approach appropriate?|
KJ Biehl, FM Kong, F Dehdashti, JY Jin, S Mutic, I El Naqa, BA Siegel, ...
Journal of Nuclear Medicine 47 (11), 1808-1812, 2006
|Positron emission tomographic assessment of” metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy|
F Dehdashti, FL Flanagan, JE Mortimer, JA Katzenellenbogen, MJ Welch, ...
European journal of nuclear medicine 26 (1), 51-56, 1999
|Positron tomographic assessment of 16α-[18F] fluoro-17β-estradiol uptake in metastatic breast carcinoma|
AH McGuire, F Dehdashti, BA Siegel, AP Lyss, JW Brodack, CJ Mathias, ...
Journal of Nuclear Medicine 32 (8), 1526-1531, 1991
|Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma|
JK Schwarz, BA Siegel, F Dehdashti, PW Grigsby
Jama 298 (19), 2289-2295, 2007
|The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival|
EA Kidd, BA Siegel, F Dehdashti, PW Grigsby
Cancer 110 (8), 1738-1744, 2007
|Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.|
FL Flanagan, F Dehdashti, OA Ogunbiyi, IJ Kodner, BA Siegel
Annals of surgery 227 (3), 319, 1998